| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H20ClN3O |
| Molecular Weight | 341.835 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC(=O)N(C)CC1=C(N=C2C=CC=CN12)C3=CC=C(Cl)C=C3
InChI
InChIKey=LIFDPEORUVTOCP-UHFFFAOYSA-N
InChI=1S/C19H20ClN3O/c1-3-6-18(24)22(2)13-16-19(14-8-10-15(20)11-9-14)21-17-7-4-5-12-23(16)17/h4-5,7-12H,3,6,13H2,1-2H3
| Molecular Formula | C19H20ClN3O |
| Molecular Weight | 341.835 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Synthélabo developed a saripidem (also known as SL 850274) as a potential anxiolytic agent that modulates the benzodiazepine-binding site on GABAA receptor via primary binding with ω1 subtype. Saripidem was studied in phase II clinical trials for the treatment of patients with anxiety disorders. However, information about the further development of the drug is not available.
